Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore,Expert Review of Pharmacoeconomics & Outcomes Research

当前位置： X-MOL 学术 › Expert Rev. Pharmacoecon. Outcomes Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore
Expert Review of Pharmacoeconomics & Outcomes Research ( IF 2.3 ) Pub Date : 2024-01-25 , DOI: 10.1080/14737167.2023.2291155
Boon Piang Cher ₁ , Sharon Goh ₁ , Mohamed Ismail Abdul Aziz ₁ , Grace Wong ₁ , Raymond Ng Chee Hui ₂ , Benjamin Shao-Kiat Ong ₁ , Kwong-Hoe Ng ₁

Affiliation

To assess the cost-effectiveness of sacituzumab govitecan for treating relapsed or refractory metastatic triple-negative breast cancer (TNBC) in Singapore.A three-state partitioned survival model w...

中文翻译：